GenMark Diagnostics, Inc., a supplier of self-regulating, multiplex diagnostic tools for molecular systems, proclaimed that their company’s ‘eSensor Warfarin Sensitivity Test’ has been chosen for an important clinical Warfarin test called the WARFARIN Trial (Warfarin Adverse event Reduction for Adults Receiving genetic testing at therapy INitiation). The unique test will analyze the significance of genetic examination for lowering the detrimental effects linked with the Warfarin treatment.
The Centers for Medicare and Medicaid Services (CMS) will refund the entitled patients undergoing the clinical study by assigning a temporary code thus permitting their pharmacogenomic evaluation to be carried out under the Coverage with Evidence Development (CED) plan according to the Social Security Act.
Iverson Genetics, a leading provider of operative genetic data to the physicians, has opted for GenMark’s tool for the WARFARIN test. According to Dean Sproles, Iverson Genetics’ CEO, they had chosen GenMark’s technology due to its capability in furnishing secure and precise diagnostic results and that the XT-8 enables speedy processing and easy portrayal of the patient’s test results.
Christopher Gleeson, CEO, GenMark Diagnostics stated that their eSensor XT-8 system is user-friendly and will serve wide applications in research institutes and clinical laboratories.